TNF and COVID-19: We found that among IBD patients infected by COVID-19, anti-TNF agents were associated with lower incidences of hospitalization (OR 0.46, 95% CI 0.39-0.54, P<0.01), ICU (OR 0.37, 95% CI 0.25-0.54, P<0.01), ventilation (OR 0.30, 95% CI 0.19-0.48, P<0.01), and death (OR 0.21, 95%CI 0.11-0.38, P<0.01).